Initial Therapeutics is a developer of small-molecule medicines designed to prevent pathogenic protein synthesis.
Initial Therapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
Initial Therapeutics's investors include Apple Tree Partners.
Initial Therapeutics is headquartered in South San Francisco, United States.
Initial Therapeutics is a developer of small-molecule medicines designed to prevent pathogenic protein synthesis.
Initial Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Initial Therapeutics — Funding & Investors." VCBacked, May 1, 2023, https://www.vcbacked.co/company/initial-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Initial Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/initial-therapeutics
{{cite web |title=Initial Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/initial-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated